November 6, 2024 10:34 AM EST
News Briefing

Macro­Gen­ics paus­es de­vel­op­ment of ADC; Cel­lec­tis de­pri­or­i­tizes CAR-T

ENDPOINTS

Plus, news about Tan­go Ther­a­peu­tics, En­do, Neu­ro­gene and Cen­tu­ry Ther­a­peu­tics:

Macro­Gen­ics stopped dos­ing pa­tients in ADC tri­al: Af­ter three pa­tient deaths in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times